arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Protagonist Therapeutics, Inc

PTGX
$145.99 ▼ -0.33 (-0.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protagonist Therapeutics, Inc faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $9.3B
Dividend Yield
Revenue Growth -89.4%
Op. Margin -343.6%
ROIC -25.9%
FCF / Share $0.88
Trailing P/E
Price / Book 14.9x
FCF Yield 0.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$46.02M
↓ -89.4%
Net Income Profit after all expenses
$-130.15M
↓ -147.3%
Operating Margin Operating profit as % of sales
-343.6%
↓ -690.4% 0th
FCF / Share Free cash flow per share
$0.88
↓ -70.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
34
Returns
27
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 46 quarters